钆塞酸增强MRI在结直肠癌患者化疗所致局灶性结节性增生样病变与肝转移瘤鉴别诊断中的作用
回顾性分析30例结直肠癌化疗后患者共82个FNH样病变与30例患者共49个肝转移瘤的钆塞酸增强MRI表现,两组各期信号强度差异均有统计学意义(p<0.05);FNH样病变肝胆期呈三种强化模式,随访中病变大小可稳定、增大或缩小/消失。结论认为钆塞酸增强MRI可鉴别化疗所致FNH样病变与肝转移瘤。
要点
- 化疗所致FNH样病变肝胆期以环状强化最常见(73.2%),另见高/等信号(18.3%)与不均匀高信号(8.5%)。
- FNH样病变从化疗结束至出现的中位时间为31个月,随访4-87个月中56.16%稳定、28.77%增大、15.07%缩小或消失。
- 两组各期MRI表现差异均有统计学意义(p<0.05),支持钆塞酸增强MRI用于鉴别。
核心结论
- 钆塞酸增强MRI可区分结直肠癌患者化疗所致FNH样病变与肝转移瘤;FNH样病变肝胆期呈三种强化模式,随访中大小变化多样。
研究设计与样本
- 回顾性分析本院接受化疗及钆塞酸增强MRI的结直肠癌患者,按影像特征和病理结果分为FNH样病变组(30例,82个病变)与肝转移瘤组(30例,49个病变),由两名腹部放射科医师对比各期信号强度。
关键影像表现/征象
- FNH样病变肝胆期强化模式:高信号/等信号占18.3%,不均匀高信号占8.5%,环状强化占73.2%。
- 两组所有MRI表现差异均有统计学意义(p<0.05)。
- 随访4-87个月,27例患者73个病变中41个(56.16%)稳定、21个(28.77%)增大、11个(15.07%)缩小或消失。
诊断标准与关键数值
- FNH样病变从化疗结束至出现的中位时间为31个月。
- FNH样病变肝胆期分为高信号/等信号、不均匀高信号和环状强化三种模式,构成比分别为18.3%、8.5%、73.2%。
临床应用与阅片要点
- 对结直肠癌化疗后新发肝病变,应结合钆塞酸增强MRI肝胆期强化模式鉴别FNH样病变与肝转移瘤。
- FNH样病变在随访中可稳定、增大或缩小/消失,随访观察其大小变化有助于判断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To describe the gadoxetic acid-enhanced magnetic resonance imaging (MRI) features and follow-up changes of hepatic focal nodular hyperplasia (FNH)-like lesions induced by chemotherapy in patients with colorectal cancer (CRC) and the differential diagnosis of FNH-like lesions and liver metastases.
METHODS: We retrospectively analyzed the data of patients with CRC who received chemotherapy and gadoxetic-enhanced MRI at our hospital. Based on imaging features and pathological findings, the patients were classified into two groups: FNH-like lesions and liver metastases. Two abdominal radiologists reviewed and compared the signal intensities of all images in each phase for both groups. The characteristics of the FNH-like lesions in the hepatobiliary phase were evaluated, and changes in size of lesions were monitored.
RESULTS: Thirty patients with 82 FNH-like lesions and 30 with 49 liver metastases following chemotherapy were included in the study. All MRI findings were statistically significantly different between the two groups (p < 0.05). In FNH-like lesions, three enhancement patterns were observed in the hepatobiliary phase: hyperintense/isointense (18.3%), heterogeneous hyperintense (8.5%), and ring-like enhancement (73.2%). The median time from completion of chemotherapy to development of FNH-like lesions was 31 months. During 4-87 months of follow-up, 27 patients with 73 lesions showed the following outcomes: 41 lesions (56.16%) showed stability, 21 lesions (28.77%) growth, and 11 lesions (15.07%) reduction or disappearance.
CONCLUSION: Gadoxetic acid-enhanced MRI can distinguish between chemotherapy-induced FNH-like lesions and liver metastases in patients with CRC. The FNH-like lesions exhibited three enhancement patterns in the hepatobiliary phase, and the changes varied during follow-up.
引用
- Chen YY, Wang ML, Li Y, et al. Role of gadoxetic acid-enhanced MRI in the differential diagnosis of chemotherapy-induced focal nodular hyperplasia-like lesions and liver metastases in patients with colorectal cancer. Abdom Radiol (NY). 2024. PMID: 39347974. doi:10.1007/s00261-024-04614-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。